Expansion brings AI-powered care coordination to underserved communities for clinical trial recruitment

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced the expansion into outpatient ambulatory centers to accelerate clinical trial recruitment. Amavita Heart and Vascular Health™, with facilities spanning four locations in Miami-Dade County, has taken a pioneering step by integrating Viz.ai technology into their outpatient ambulatory centers to screen and recruit patients in a clinical study on heart failure, sponsored by a leading, global biopharma company.

“We pride ourselves on research and the impact that it can have on new discoveries,” said Pedro Martinez-Clark, MD, founder of Amavita Heart and Vascular Health™. “Having an AI-powered platform that integrates with our EMR system will allow us to save valuable time and resources often involved with manual chart reviews for research studies.”

Viz.ai’s expansion into outpatient clinics allows both ambulatory and hospital-based research sites to access the artificial intelligence (AI)-powered platform, Viz RECRUIT, to aid with patient identification and patient recruitment for clinical research. With 80% of clinical studies failing to meet their enrollment timeline target¹, reducing time in patient screening and identification can help get novel therapies to patients sooner. Viz RECRUIT integrates with healthcare IT systems of record (e.g., electronic health records, core labs) to simplify the screening process. The AI-powered solution identifies eligible clinical trial candidates and connects the research team to accelerate clinical trial enrollment in a secure, compliant mobile application.

“Heart failure patients who may be eligible for clinical trials are seen across a number of different healthcare settings,” said Jayme Strauss, chief clinical officer at Viz.ai. “By deploying Viz.ai in outpatient clinics, we are not only reducing the manual burden of patient identification on research staff but also reaching underserved and diverse clinical trial populations.”

Outpatient care for heart failure has increased.² In 2016, there were 1,932,000 office visits and 414,000 emergency department visits with a primary diagnosis of heart failure.² By 2030, it is estimated that more than 8 million individuals in the United States (U.S.) will have heart failure for a prevalence rate of 1 in every 33 individuals.² The annual cost of caring for a patient with heart failure is near $30,000 in the U.S., with U.S. heart failure costs expected to reach at least $70 billion per year by 2030 ($244 per every U.S. adult) with the total cost of caring for patients with heart failure reaching $160 billion.² Most of this cost comes from inpatient care. By identifying patients in the outpatient setting before a patient is hospitalized, Viz.ai is aiding access to early treatment and potentially helping to reduce overall costs for heart failure.

To learn more about Viz.ai for clinical research, please visit https://www.viz.ai/clinical-trial-enrollment.

About Viz.ai, Inc.

Viz.ai is the pioneer in the use of AI algorithms and machine learning to increase the speed of diagnosis and care, covering more than 220 million lives across 1,400+ hospitals and health systems in the U.S. and Europe. The AI-powered Viz.ai Platform is an intelligent care coordination solution that identifies more patients with a particular disease, informs critical decisions at the point of care, and optimizes care pathways and helps improve outcomes. Backed by real-world clinical evidence, the Viz.ai Platform delivers significant value to patients, providers, and pharmaceutical and medical device companies. For more information visit viz.ai.

¹Desai M. Recruitment and retention of participants in clinical studies: Critical issues and challenges. Perspect Clin Res. 2020;11(2):51-53. doi:10.4103/picr.PICR_6_20

²Virani SS, Alonso A, Benjamin EJ, et al. Heart Disease and Stroke Statistics-2020 Update: A Report From the American Heart Association. Circulation. 2020;141(9):e139-e596. doi:10.1161/CIR.0000000000000757

View source version on businesswire.com: https://www.businesswire.com/news/home/20230926386974/en/